The acute effect of cigarette smoking on the high-sensitivity CRP and fibrinogen biomarkers in chronic obstructive pulmonary disease patients

Biomarkers in Medicine

Volumn 7, Issue 2, 2013, Pages 211-219

  Van Dijk, Wouter D ^a   Akkermans, Reinier ^a   Heijdra, Yvonne ^a   Weel, Chris Van ^a   Schermer, Tjard RJ ^a   Scheepers, Paul TJ ^a   Lenders, Jacques WM ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

biomarker; chronic obstructive pulmonary disease; cigarette; COPD; fibrinogen; high sensitivity CRP; smoking

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; FIBRINOGEN; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84875827046     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.112     Document Type: Article

References (38)

1. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 111(20), 2684-2698 (2005). (Pubitemid 40740869)
2. McGhee SM, Ho SY, Schooling M et al. Mortality associated with passive smoking in Hong Kong. BMJ 330(7486), 287-288 (2005). (Pubitemid 40203643)
3. Wen W, Shu XO, Gao YT et al. Environmental tobacco smoke and mortality in Chinese women who have never smoked: prospective cohort study. BMJ 333(7564), 376 (2006).
4. WHO. IAFROC Monographs on the Evaluation of Carcinogenic Risks to Humans. WHO Press, Switzerland, 83 (2002).
5. Teo KK, Ounpuu S, Hawken S et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368(9536), 647-658 (2006 (Pubitemid 44223693)
6. Willett WC, Green A, Stampfer MJ et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N. Engl. J. Med. 317(21), 1303-1309 (1987). (Pubitemid 17153011)
7. Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328(7455), 1519 (2004).
8. Hoffmann D. Chapter D: Analysis of toxic smoke constituents. In: Toxicity Testing Plan Volume 5. US Consumer Product Saftey Commission, Washinton, DC, USA, D1-D38 (1993).
9. Pryor WA, Stone K, Zang LY et al. Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem. Res. Toxicol. 11(5), 441-448 (1998). (Pubitemid 28242488)
10. Smith LE, Denissenko MF, Bennett WP et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl Cancer Inst. 92(10), 803-811 (2000). (Pubitemid 30368036)
11. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol. 43(10), 1731-1737 (2004). (Pubitemid 38622506)
12. Yanbaeva DG, Dentener MA, Creutzberg EC et al. Systemic effects of smoking. Chest 131(5), 1557-1566 (2007). (Pubitemid 46762366)
13. Antoniu SA. Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers 15(2), 97-103 (2010).
14. Vestbo J, Edwards LD, Scanlon PD et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 365(13), 1184-1192 (2011).
15. Man SF, Connett JE, Anthonisen NR et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61(10), 849-853 (2006). (Pubitemid 44570304)
16. Garg A. What is the role of alternative biomarkers for coronary heart disease? Clin. Endocrinol. (Oxf.) 75(3), 289-293 (2011).
17. Armitage AK, Dixon M, Frost BE et al. The effect of inhalation volume and breath-hold duration on the retention of nicotine and solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking. Contrib. Tobacco Res. 21(4), 240-249 (2004).
18. Barua RS, Sy F, Srikanth S et al. Acute cigarette smoke exposure reduces clot lysis-association between altered fibrin architecture and the response to t-PA. Thromb. Res. 126(5), 426-430 (2010).
19. Barua RS, Sy F, Srikanth S et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler. Thromb. Vasc. Biol. 30(1), 75-79 (2010).
20. Papaioannou AI, Koutsokera A, Tanou K et al. The acute effect of smoking in healthy and asthmatic smokers. Eur. J. Clin. Invest. 40(2), 103-109 (2010).
21. Kimura S, Nishinaga M, Ozawa T et al. Thrombin generation as an acute effect of cigarette smoking. Am. Heart J. 128(1), 7-11 (1994). (Pubitemid 24227129)
22. van Dijk W, Scheepers P, Cremers R et al. A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial. Trials 12(1), 37 (2011).
23. van Dijk WD, Heijdra Y, Scheepers PT, Lenders JW, van Weel C, Schermer TR. Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Med. Hypotheses 74, 277-280 (2010).
24. Benowitz NL, Porchet H, Sheiner L, Jacop P 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 44(1), 23-28 (1988).
25. Broekhuizen R, Wouters EF, Creutzberg EC et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61(1), 17-22 (2006). (Pubitemid 43106972)
26. Abd TT, Eapen DJ, Bajpai A et al. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr. Atheroscler. Rep. 13(2), 154-161 (2011).
27. Bossuyt PM. The thin line between hope and hype in biomarker research. JAMA 305(21), 2229-2230 (2011).
28. Clyne B, Olshaker JS. The C-reactive protein. J. Emerg. Med. 17(6),1019-1025 (1999). (Pubitemid 29528076)
29. Shainoff JR, DiBello PM. The circulatory half-lives of a-profibrin monomer, and comparisons with other fibrin(ogen) derivatives. Thromb. Haemost. 89(1), 48-52 (2003). (Pubitemid 36149792)
30. Charm SE, Wong BL. Shear degradation of fibrinogen in the circulation. Science 170(3956), 466-468 (1970).
31. Verstraete M, Amery A, Vermylen J et al. Practical method for thrombolytic therapy with streptokinase. Maintenance of nearly complete plasminogen depletion associated with high circulating activator activity. BMJ 1(5384), 675-676 (1964).
32. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 141(1), 133-139 (1998). (Pubitemid 28539424)
33. Davis MC. Oral contraceptive use and hemodynamic, lipid, and fibrinogen responses to smoking and stress in women. Health Psychol. 18(2), 122-130 (1999). (Pubitemid 29152600)
34. Dahl M, Vestbo J, Zacho J, Lange P, Tybjaerg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 66, 197-204 (2011).
35. van Durme YM, Lahousse L, Verhamme KM et al. Mendelian randomization study of interleukin-6 in chronic obstructive pulmonary disease. Respiration 82, 530-538 (2011).
36. Centers for Disease Control and Prevention. Smoking and Tobacco Use fact sheets. www.cdc.gov/tobacco/data-statistics/fact- sheets/index.htm (Accessed November 2011
37. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org (Accessed February 2012
38. UpToDate. Cardiovascular risk of smoking and benefits of smoking cessation. www.uptodate.com/contents/ cardiovascular-risk-of-smoking-and- benefits-of-smoking-cessation (Accessed March 2010